Trial Profile
A Phase 2, Open-label, Uncontrolled, Single-dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Occurrence of Antidrug Antibody for Nirsevimab in Immunocompromised Children ≤ 24 Months of Age
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Nirsevimab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Acronyms MUSIC
- Sponsors AstraZeneca; AstraZeneca AB; MedImmune
- 12 Dec 2023 Results evaluating the safety, pharmacokinetics (PK), and emergence of antidrug antibodies (ADA) in immunocompromised children months of age,presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 14 Apr 2023 According to an AstraZeneca media release, results from this trial will be presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), 2023.
- 16 Mar 2023 Status changed from active, no longer recruiting to completed.